In addition, combining IL-13/STAT6 with serum AFP also increased predictive capacity of serum AFP and increased its sensitivity and accuracy in predicting HCC development in low fibrosis grades, F1 and F2 NASH patients. Here, AFP is linked to metabolic dysfunction-associated steatohepatitis.